Signature 11, which is associated with exposure to temozolomide plus MGMT promoter and/or mismatch repair deficiency,51 was indeed present in tumors with previous exposure to the drug (Table 2). This evidence concerns the gene MGMT and mismatch repair cancer syndrome 1.